Nicholas Poirier

Nicholas Poirier

Company: OSE Immunotherapeutics

Job title: CSO


CLEC-1 : Novel Don’t Eat Me signal Regulating Anti-Tumor Responses 2:00 pm

CLEC-1 inhibits dendritic cells antigen cross-presentation and macrophage phagocytosis in synergy with tumortargeting mAb Cell stress/death induced by radiation or chemotherapy increased CLEC-1 ligand expression Increased anti-tumor responses in vivo in CLEC-1 KO mice and synergy with chemotherapyRead more

day: Discovery & Pre-Clinical Development - Day 1 pm

ChemR23 Agonist mAb: Triggering the Resolution of Inflammation 12:30 pm

ChemR23 over-expression in inflamed tissues and tumors in man Agonist mAb against particular ChemR23 epitopes induces receptor signaling, macrophages reprogramming and neutrophils apoptosis Preclinical efficacy demonstrated in both chronic inflammation and oncology modelsRead more

day: Focus Day

Industry Leader’s Fireside Chat 10:30 am

An executive panel discussion from the C-level leaders of the field to set the scene on macrophage directed therapy development. Ask your questions live to understand the expert’s thoughts on key topics including safety and toxicity management, controlling the plasticity of macrophages and exploring the immunological memory of macrophagesRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.